news
Biopharma sees strong Q2 2023 market cap growth
Johnson & Johnson have been shifted from the top position in the market capitalisation ranking for the first time, due to Eli Lilly having the largest growth during Q2 2023, research shows.
List view / Grid view
Taltz
news
EMA recommends eight drugs for approval from April meeting
The EMA's human medicines committee has adopted a positive opinion for eight medicines, recommending their marketing authorisation.
news
British Columbia first province to switch patients to biosimilars
British Columbia has said it will switch as many as 20,400 patients from three branded biologic drugs to cheap biosimilars.
news
Lilly’s psoriasis drug Taltz to generate sales over $1 billion by 2022
11 May 2016 | By Victoria White, Digital Content Producer
Lilly’s psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its high clinical efficacy and good safety profile, according to an analyst with research and consulting firm GlobalData.
